In glioblastoma cells treated with Plinabulin at 50 nM for 24 hr, RNA-sequence analysis identified 2664 differentially expressed genes. In glioblastoma, Plinabulin treatment at 0, 4, 8, and 16 nM produced a significant, dose-dependent reduction in p-mTOR and p-AKT expression levels. [1]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Plinabulin alters gene expression in glioblastoma cells
Cell-based study · glioblastoma cells [1]
Glioblastoma cells were treated with Plinabulin at 50 nM for 24 hr. RNA-sequence analysis identified 2664 differentially expressed genes regulated by Plinabulin.
Literature-Reported Treatment Conditions
- Treatment concentration
- 50 nM
- Exposure duration
- 24 hr
- Method
- treated with Plinabulin
- Vehicle
- DMSO
Methods and source locations
Compound reported in the paper: Plinabulin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods (S2, S43); Results (S66, S67)
RNA-sequence analysis: RNA-sequence analysis; comparator: DMSO — Materials and Methods (S43); Results (S66, S67)
Plinabulin reduces p-mTOR and p-AKT expression in glioblastoma
Cell-based study · glioblastoma [1]
In glioblastoma, treatment with Plinabulin at 0, 4, 8, and 16 nM produced a significant, dose-dependent reduction in p-mTOR and p-AKT expression levels.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 4, 8, and 16 nM
- Method
- treatment with plinabulin
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: schedule.
Methods and source locations
Compound reported in the paper: Plinabulin
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods (S2); Results (S79, S90)
p-mTOR and p-AKT expression levels: p-mTOR and p-AKT expression levels; comparator: 0 nM — Results (S90)
